Kinney JL. Nomifensine maleate: a new second-generation
antidepressant. Clin Pharm 1985;4:625-636
Nomifensine withdrawn by manufacturer. FDA Drug Bull
1986;16:7-8
Hoechst-Roussel Pharmaceuticals Inc.. Withdrawal
of Merital. Somerville, NJ: Hoechst-Roussel Pharmaceuticals
Inc., January 1986
Mamelok RD. Drug discovery and development. In: Melmon KL,
Morrelli HF, Hoffman BB, Nierenberg DW, eds. Melmon and
Morrelli's Clinical Pharmacology: Basic Principles in
Therapeutics. 3rd ed. New York: McGraw-Hill, Inc;
1992:911-921
Venning GR. Identification of adverse reactions to new
drugs. II--how were 18 important adverse reactions discovered and
with what delays? Br Med J 1983;286:289-292
Wallender M-A. The way towards adverse event monitoring in
clinical trials. Drug Saf 1993;8:251-262
Reeves PR, McCormick DJ, Jepson HT. Practolol metabolism
in various small animal species. Xenobiotica 1979;9:453-458
Rosenbaum SE, Lindup WE, Orton TC. Practolol and its
metabolites: tissue localization and retention in the hamster. J
Pharmacol Exp Ther 1985;234:485-490
MedWatch Continuing Education Article. Clinical
therapeutics and the recognition of drug-induced disease.
Goldman SA, Kennedy DL, Lieberman RL, eds. Rockville, Md: Food
and Drug Administration, June 1995
Lewis JA. Post-marketing surveillance: how many patients?
Trends Pharmacol Sci 1981;2:93-94
Kessler DA. Introducing MedWatch: a new approach
to reporting medication and device adverse effects and product
problems. JAMA 1993;269:2765-2768
American Medical Association. Reporting adverse drug and
medical device events: report of the AMA's Council on Ethical and
Judicial Affairs. Food and Drug Law Journal 1994;49:359-366
Advisory Opinion No. 1 to Section 4-A, Devices and
Therapeutic Methods, of the American Dental Association
Principles of Ethics and Code of Professional Conduct
The Journal of the American Medical Association. JAMA
instructions for authors. JAMA 1996;275:5-12
Chen RT, Rastogi SC, Mullen JR, Hayes SW, Cochi SL,
Donlon JA, et al. The Vaccine Adverse Event Reporting System
(VAERS). Vaccine 1994;12:542-550
The National Childhood Vaccine Injury Act of 1986, at
Section 2125 of the Public Health Service Act as codified at 42
U.S.C. 300aa-25(Suppl 1987)
21 CFR 803 and 807
Protecting the identities of reporters of adverse events
and patients; preemption of disclosure rules. Fed Regist 1995;
60(April 3);16962-16968
Joint Commission on Accreditation of Healthcare
Organizations. 1996 Comprehensive Accreditation Manual for
Hospitals. Oakbrook Terrace, IL: Joint Commission on
Accreditation of Healthcare Organizations, 1995
ASHP guidelines on adverse drug reaction monitoring and
reporting. Am J Health Syst Pharm 1995;52:417-419
21 CFR 314.80
21 CFR 600.80
Dietary Supplement Health and Education Act (DSHEA) of
1994
Faich GA. Adverse-drug-reaction monitoring. N Engl J Med
1986;314:1589-1592
Koch-Weser J, Sellers EM, Zacest R. The ambiguity of
adverse drug reactions. Eur J Clin Pharmacol 1977;11:75-78
Green DM. Pre-existing conditions, placebo reactions, and
"side effects". Ann Intern Med 1964;60:255-265
Reidenberg MM, Lowenthal DT. Adverse nondrug reactions. N
Engl J Med 1968;279:678-679
Karch FE, Smith CL, Kerzner B, Mazzullo JM, Weintraub M,
Lasagna L. Adverse drug reactions - a matter of opinion. Clin
Pharmacol Ther 1976;19:489-492
Rawlins MD. Pharmacovigilance: paradise lost, regained or
postponed? The William Withering Lecture 1994. J R Coll
Physicians Lond 1995;29:41-49
Strom BL, Tugwell P. Pharmacoepidemiology: current
status, prospects, and problems. Ann Intern Med
1990;113:179-181
Scott HD, Rosenbaum SE, Waters WJ, Colt AM, Andrews LG,
Juergens JP, et al. Rhode Island physicians' recognition and
reporting of adverse drug reactions. R I Med J
1987;70:311-316
Sachs RM, Bortnichak EA. An evaluation of spontaneous
adverse drug reaction monitoring systems. Am J Med 1986;81(suppl
5B):49-55
Weber JCP. Epidemiology of adverse reactions to
nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP,
eds. Advances in Inflammation Research. Vol 6. New York: Raven
Press; 1984:1-7
Begaud B, Moride Y, Tubert-Bitter P, Chaslerie A,
Haramburu F. False-positives in spontaneous reporting: should we
worry about them? Br J Clin Pharmacol 1994;38:401-404
Serradell J, Bjornson DC, Hartzema AG. Drug utilization
study methodologies: national and international perspectives.
Drug Intell Clin Pharm 1987;21:994-1001
Fletcher AP. Spontaneous adverse drug reaction reporting
vs event monitoring: a comparison. J R Soc Med
1991;84:341-344
Finney DJ. The detection of adverse reactions to
therapeutic drugs. Stat Med 1982;1:153-161
Finney DJ. Statistical aspects of monitoring for dangers
in drug therapy. Methods Inf Med 1971;10:1-8
Standardization of definitions and criteria of causality
assessment of adverse drug reactions: drug-induced liver
disorders: report of an international consensus meeting. Int J
Clin Pharmacol Ther Toxicol 1990;28:317-322
Auriche M, Loupi E. Does proof of causality ever exist in
pharmacovigilance? Drug Saf 1993;9:230-235
Temple RJ, Jones JK, Crout JR. Adverse effects of newly
marketed drugs. N Engl J Med 1979;300:1046-1047
Rossi AC, Knapp DE. Discovery of new adverse drug
reactions: a review of the Food and Drug Administration's
Spontaneous Reporting System.
JAMA1984;252:1030-1033